Phase i study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia

Rebecca B. Klisovic, William Blum, Xiaohui Wei, Shujun Liu, Zhongfa Liu, Zhiiiang Xie, Tamara Vukosavljevic, Cheryl Kefauver, Lenguyen Huynh, Jiuxia Pang, James A. Zwiebel, Steven Devine, John C. Byrd, Michael R. Grever, Kenneth Chan, Guido Marcucci

Research output: Contribution to journalArticlepeer-review

36 Scopus citations

Fingerprint

Dive into the research topics of 'Phase i study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry